TE
Trails Edge Capital Partners, LP disclosed a 5.2% stake in AVTX
Trails Edge Capital Partners, LP reported owning 5.2% of Avalo Therapeutics, Inc. (AVTX) (2,803,761 shares) in a Schedule 13G filed Oct 29, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 29, 2026
- Source
- Schedule 13G